DIAGNOSIS OF CHRONIC PSEUDOMONAS-AERUGINOSA INFECTION IN CYSTIC-FIBROSIS BY ELISA FOR ANTIPSEUDOMONAS LPS IGG ANTIBODIES

被引：8

作者：

NELSON, JW

BARCLAY, GR

GOVAN, JRW

机构：

[1] Bacteriology Department, University of Edinburgh Medical School, Edinburgh, Scotland

[2] Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh, Scotland

[3] Department of Transfusion Medicine, Royal Infirmary, Edinburgh, Scotland

来源：

SERODIAGNOSIS AND IMMUNOTHERAPY IN INFECTIOUS DISEASE | 1990年 / 4卷 / 01期

关键词：

anti-LPS antibodies; cystic fibrosis; ELISA; lipopolysaccharide; Pseudomonas aeruginosa;

D O I：

10.1016/0888-0786(90)90044-O

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An enzyme-linked immunosorbant assay (ELISA) with urease enzyme was developed with either a polyvalent pseudomonas smooth lipopolysaccharide (LPS) extract vaccine (PEV-02) or rough LPS (R-LPS) from P. aeruginosa rough mutant PAC605. Each ELISA was able to differentiate between sera from cystic fibrosis (CF) patients chronically colonized with P. aeruginosa and sera from non-colonized patients. Sera from non-colonized and intermittently colonized CF patients seldom reacted with any of the Pseudomonas LPS, whereas sera from chronically colonized CF patients reacted strongly with most of the sixteen smooth O-serotype vaccine components and with the PAC605 R-LPS, indicating the presence either of a number of different serotype specific IgG antibodies and/or IgG antibodies directed to a common antigenic component of LPS rough core. Absorption studies and immunoblot analysis demonstrated that in sera from CF patients who were chronically colonized with P. aeruginosa a significant component of the anti-P. aeruginosa antibodies is specific for the core of P. aeruginosa LPS and cross reactive with a number of serotypes of P. aeruginosa LPS. © 1990.

引用

页码：9 / 16

页数：8

共 22 条

[1]

Pier, Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction, J Infect Dis, 151, pp. 575-580, (1985)

[2]

Hoiby, Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immuno-electrophoresis, Acta Pathol Microbiol Scand Sect C Suppl, 262, pp. 3-96, (1977)

[3]

Brett, Ghoneim, Littlewood, Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study, J Clin Micro, 26, pp. 1565-1570, (1988)

[4]

Brett, Ghonheim, Littlewood, Losowsky, Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa surface antigens in sera of patients with cystic fibrosis, J Clin Pathol, 39, pp. 1124-1129, (1986)

[5]

Pedersen, Espersen, Hoiby, Diagnosis of chronic Pseudomonas aeruginosa in cystic fibrosis by enzyme linked immunosorbent assay, J Clin Microbiol, 25, pp. 1830-1836, (1987)

[6]

Rowe, Meadow, Structure of the core oligosaccharide from the lipopolysaccharide of Pseudomonas aeruginosa PAC1R and its defective mutants, Eur J Biochem, 132, pp. 329-337, (1983)

[7]

Miler, Spilsbury, Jones, Roe, Lowbury, A new polyvalent pseudomonas vaccine, J Med Microbiol, 10, pp. 19-27, (1977)

[8]

Galanos, Luderitz, Westphal, A new method for the extraction of R lipopolysaccharides, Eur J Biochem, 9, pp. 245-249, (1969)

[9]

Qureshi, Takayama, Ribi, Purification and structural determination of non-toxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium, J Biol Chem, 257, pp. 11808-11815, (1982)

[10]

Barclay, Yap, McClelland, Jones, Roe, McCann, Micklem, James, Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine, J Med Microbiol, 21, pp. 87-90, (1986)

← 1 2 3 →